High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

导出原文传递

翻译打印收藏纠错

作者： Rea D ^[1] ; Legros L ; Raffoux E ; Thomas X ; Turlure P ; Maury S ; Dupriez B ; Pigneux A ; Choufi B ; Reman O ; Stephane D ; Royer B ; Vigier M ; Ojeda Uribe M ; Recher C ; Dombret H ; Huguet F ; Rousselot P

作者单位： Service d'Hematologie Clinique, Hopital Saint-Louis, Paris, France. ^[1]

关键词 Blast Crisis Leukemia Lymphocytic Acute L2 Myeloid Chronic 原始细胞危象白血病淋巴细胞急性髓样慢性

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览4

Leukemia

2006年20卷3期

400-403页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Leukemia

相似文献

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.

Leukemia

相似文献

Leukemia

相关期刊

检索历史清除